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Received January 4, 2012; accepted May 24, 2012AbstractBackground: Inactivation of p16 by methylation of CpG islands is a frequent early event in human cancers, including papillary thyroid
carcinoma (PTC). This study was to observe the methylation status of the p16 gene in papillary thyroid carcinoma (PTC) and its correlation with
clinical parameters.
Methods: Methylation-specific PCR (MSP) was used to analyze the methylation status of the p16 gene in 74 PTCs and 21 adjacent normal
thyroid tissues.
Results: Hypermethylation of p16 gene was observed in 27.0% (20/74) of PTC. None of the normal thyroid tissues was methylated, when
compared to the PTCs ( p < 0.05). There was no marked relationship between the methylation of p16 gene and the patients’ age, gender, size of
cancer, histological subtypes and occurrence of recurrent disease ( p > 0.05). The methylation of p16 gene was positively associated with
metastasis, a high AMES (age, metastasis to distant sites, extrathyroidal invasion, size) risk group ( p < 0.05) and advanced pathological
tumorelymph nodeemetastasis stages.
Conclusion: The methylation of the p16 gene, one event of significance in molecular biology, was common and correlated with biological
metastasis and histological features in PTC, and may be involved in thyroid tumorigenesis and aggressiveness.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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1. Introduction three main mechanisms that alter the p16 gene: homozygousThe P16 suppressor gene is one of the most commonly
studied candidates in the pathogenesis of human neoplasia,
belonging to a class of cyclin-dependent kinase (CDK)
inhibitory proteins. It binds specifically to CDK 4 and inhibits
the catalytic activity of the CDK-cyclin D complex, a key
regulator of the G1 checkpoint of the cell cycle.1 There are* Corresponding author. Dr. Baoguo Liu, Key Laboratory of Carcinogenesis
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and Department of Head and Neck Surgery, Peking University School of
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http://dx.doi.org/10.1016/j.jcma.2012.11.007deletion, promoter hypermethylation, and, very rarely, point
mutations.2 In particular, promoter hypermethylation of CpG
islands has been shown to be an epigenetic change resulting in
loss of function of responsive genes involved in cell cycle
regulation and DNA repair. Methylation of p16 CpG islands
silences transcription of this gene.3 It has been observed that in
primary gastric carcinoma (GC), the frequency of p16 inacti-
vation by homozygous deletions ranges 0e9%, by mutation
0e2%, while by methylation 32e42%,4e10 which suggests
that methylation is a major mechanism for p16 inactivation in
GC. Moreover, p16 methylation is significantly correlated with
progression of GCs.11 In addition, it was reported that the p16-hinese Medical Association. All rights reserved.
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metastasis in non-small-cell lung cancers.12
Papillary thyroid carcinoma (PTC) is the most common
malignancy originating in the thyroid gland, and accounts for
about 60% of adult thyroid carcinomas and 100% of childhood
thyroid carcinomas. With respect to gene alterations in carci-
nogenesis, RET, BRAF, and RASSF1A genes have been noted
in a substantial number of patients with PTC.13,14 However, our
understanding of the pathway toward carcinogenesis in PTC is
incomplete, in part because abnormalities in the control of cell
cycle checkpoints are common in carcinogenesis. As for p16
inactivation in PTC, some previous studies15e18 have demon-
strated that hypermethylation of the 50 CpG island of p16 are
common and critical events, responsible for the development of
PTC, rarely by mutation. Moreover, Lam et al.18 reported p16
mRNA or p16 protein was detected in 77% and 89% of PTC,
respectively, indicating that the overexpression of p16 rather
than the loss of its protein contributes to the pathogenetic
mechanism of PTC. These findings imply that methylation of
CpG islands of p16 may also play a role in increasing the
occurrence and metastatic potential of PTC as an epigenetic
event during disease progression.
In this study, a total of 74 PTC tissues and 21 adjacent
normal thyroid tissues were evaluated using methylation-
specific PCR (MSP) to assess hypermethylation in the p16
gene implicated in regulatory processes, revealing a progres-
sive increase of p16 alterations within thyroid tumorigenesis
and from primary carcinomas to metastatic lesions. The results
showed statistically significant correlations between p16
methylation and certain clinical features of the tumors.
2. Methods2.1. PTC samples and cell linesA total of 74 PTCs including 37 primary and 37 metastatic
tumors, and 21 adjacent normal thyroid tissues from primary
(10 cases) and metastatic (11 cases) tumors were obtained
from patients from the Beijing Cancer Hospital by surgical
resection (with their informed consent) between 2004 and
2010 and were stored at 70C until use. Treated patients
received routine clinical and sonographic follow-up every 3e6
months. The follow-up period ranged from 6 months to 7 years
9 months (mean, 21 months). During the follow-up period,
cervical lymph node involvement was verified in five patients
(6.76%). Distant metastases (bone or lung) developed in two
patients (2.63%). All clinical samples and histopathological
information for each case were obtained according to
approved institutional guidelines. A tumor risk profile was
assigned according to commonly adopted AMES (age,
metastasis to distant sites, extrathyroidal invasion, size) risk
group stratification and the Union for International Cancer
Control (UICC) pTNM (pathological tumorelymph
nodeemetastasis) staging.
Human gastric cancer cell line AGS and MGC803, serving
as p16 promoter methylation and unmethylation, were
cultured in RPMI 1640 medium (Gibco, Carlsbad, CA, USA)supplemented with 10% fetal bovine serum (Gibco) at 37C
with 5% CO2.
This study was approved by the Research and Ethical
Committee of Peking University School of Oncology.2.2. DNA extractionDNA was extracted from frozen thyroid tissue and tissue
culture cells by standard sodium dodecyl sulfate (LookChem,
Shijiazhuang, China)/proteinase K (SBS Genetech, Beijing,
China) digestion followed by organic extraction and ethanol
precipitation.2.3. Sodium bisulfite treatmentOne microgram of genomic DNA was denatured in 0.2 M
NaOH (Guide Chem, Beijing, China) for 10 minutes at 37C.
The denatured DNAwas diluted in 500 mL of freshly prepared
solution of 10 mM hydroquinone (Yaou Chemicals Co. Ltd,
Taiyuan, China) and 3 M sodium bisulfite (JinRuiQi Chemical
Co. Ltd, Tianjin, China) and incubated for 16 h at 50C. After
incubation, the DNA sample was desalinized through a column
(Wizard DNAClean-Up System; Promega,Madison,WI, USA),
treated with 0.3 M NaOH for 10 minutes at room temperature,
and precipitated with ethanol. The bisulfite-modified genomic
DNAwas resuspended in 40 mL of H2O and stored at 20C.2.4. Methylation-specific PCR of p16DNA methylation status for all cell lines and PTC were
determined by MSP, which is sufficiently sensitive to detect
a single methylated allele among 1000 unmethylated ones and,
therefore, may be the most appropriate methodology for
identifying DNA methylation patterns within CpG islands of
p16. MSP distinguishes unmethylated from methylated alleles
based on sequence changes produced after bisulfite treatment
of DNA, which converts only unmethylated cytosine to uracil,
and subsequent PCR using primers designed for either meth-
ylated or unmethylated DNA.
Therefore, we utilized MSP to analyze the methylation
status of the bisulfite-modified p16 CpG islands. Both the p16-
M and p16-U primer sets for the methylated p16 CpG
islands.19 were 50-TTATTAGAGGGTGGGGCGGATCGC-30
(sense p16-M), 50-GACCCCGAACCGCGACCGTAA-30
(antisense p16-M), 50-TTATTAGAGGGTGGGGTGGATTGT-
30 (sense p16-U), and 50-CAACCCCAAACCACAACCATAA-
30 (antisense p16-U).
The PCR products of p16 CpG islands were amplified by
hot-start PCR. HotStarTaq DNA polymerase (QIAGEN
GmbH, Hilden, Germany) was used. Thermal cycler condi-
tions were denaturing at 95C for 15 minutes, amplified for 35
cycles (95C for 40 seconds, 62C for 40 seconds, 72C for
40 seconds), with extension at 72C for 10 minutes. The
reaction mixture (20 mL) contained about 10 ng of templates,
4 pmol of each primer, 4 nmol of dNTP, and 1 unit of Hot-
StarTaq DNA polymerase. Distilled water and genomic DNA
of the p16 unmethylated MGC803 cells were used as template
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was used as positive control. These controls were used in each
individual MSP experiment. The methylated p16 MSP prod-
ucts could be amplified with the p16-M in the positive control,
but not in the negative controls. The MSP products were run
on 2% agarose gel.2.5. Statistical evaluationStatistical analysis was carried out using SPSS 11.5 (SPSS
Inc., Chicago, IL, USA). Categorical variables were plotted in
contingency tables and evaluated using Fisher’s exact test.
Mean methylation index between analyzed groups was eval-
uated using the independent t test. All reported p-values are
two-sided and considered significant at p < 0.05.
3. Results
To determine the role of p16 gene inactivation in the
pathogenesis of PTCs, the methylation status of p16 CpGFig. 1. MSP of the p16 CpG island. The methylation status of the p16 promoter reg
1e37), without metastases (No. 38e74) and normal thyroid tissues (No. N1e21). M
The methylation-specific products (150 bp) and unmethylation-specific products (15
line AGS DNA and MGC803 DNA were used as controls for MSP.islands, which have been found to play a role in tumorigenesis,
were analyzed by MSP in 95 tissues including 74 PTCs and 21
normal tissues. As shown in Fig. 1, p16 promoter methylation
was noted in 20 of 74 (27%) tumor tissues, but 21 normal
tissues did not show any evidence of p16 promoter methyla-
tion ( p ¼ 0.005). The clinicopathological features of these
tumors were studied in reference to both AMES criteria and
pTNM staging system (Table 1). There was no statistical
difference between p16 hypermethylated PTCs and unme-
thylated ones with respect to age ( p ¼ 0.067), sex ( p ¼ 1.0),
histological subtypes ( p ¼ 0.666), size of cancer ( p ¼ 0.09),
or occurrence of recurrent disease ( p ¼ 0.604). However, p16
methylation was detected in 15 of 37 (40.5%) PTCs with
metastases and in only five of 37 (13.5%) PTCs without
metastases ( p ¼ 0.009), which indicates that hypermethylation
of the p16 promoter was significantly associated with malig-
nancy and metastasis. Patients in the high AMES risk group
more frequently had PTC showing methylation of the p16
promoter compared with low-risk-group patients ( p ¼ 0.0003,
Fisher’s test). In addition, patients with advanced-stage diseaseion was analyzed by MSP in papillary thyroid carcinoma with metastases (No.
ethylation- (M ) and unmethylation-specific (U ) primers were used for MSP.
1 bp) were resolved on 2% agarose gel with a 100-bp DNA ladder. Cancer cell
Table 1
Clinicopathological parameters of p16 methylation in papillary thyroid
carcinoma.
Parameter Methylated
(n ¼ 20)
Unmethylated
(n ¼ 20)
p
Sex (M:F) 4:16 10:44 1.0
Age (mean  SD, y) 52  11.84 41  11.69 0.067
Tumor size (mean  SD, cm) 2.6  1.71 2.1  1.34 0.09
Tumor histology
Conventional 19 48 0.666
Follicular variant 1 6
PTC with metastases 15 22 0.009
PTC without metastases 5 32
pTNM stage
I 3 26 0.075
II 4 7
III 10 15
IV 3 6
AMES risk group
Low 7 43 0.0003
High 13 11
Disease recurrence 6 13 0.604
AMES ¼ age, metastasis to distant sites, extrathyroidal invasion, size;
pTNM ¼ pathological tumorelymph nodeemetastasis stage.
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with those having less advanced disease. However, the
difference did not reach statistical significance ( p ¼ 0.075,
Fisher’s test).
4. Discussion
The mechanistic association between aberrant promoter
region CpG island methylation and transcriptional silencing is
complex. In normal cells, most promoter region CpG islands
are unmethylated and maintain a transcriptionally favorable
local chromatin configuration.20 Aberrant methylation of these
normally unmethylated CpG islands is associated with
underacetylated histones and a shift to a transcriptionally
repressive chromatin structure.21,22
In our study, we investigated the level of promoter hyper-
methylation of p16 gene in PTC as compared with those levels
in adjacent normal tissues. Results showed that the frequency
of p16 methylation in PTC was 27% ( p < 0.05), which
suggests that it is a frequent molecular biology occurrence in
PTC, probably resulting in tumorigenesis as an active induced
factor. At the same time, to understand better the role of
promoter hypermethylation status in the natural history of
PTC and as a molecular predictor of disease progression, we
evaluated the association between gene hypermethylation and
clinicopathological characteristics of primary PTC. It was
concluded that p16 promoter methylation were often associ-
ated with a high AMES risk group and advanced pTNM stages
but had no correlation to sex or disease recurrence.
In addition, a much higher positive rate and average
proportion of methylated p16 were detected in PTC (n ¼ 37)
with metastases (local or distant) than PTC (n ¼ 37) without
metastases. This does not exclude the possibility that the
primary tumor was heterogenous and that only a small
subpopulation of the primary tumor cells metastasized.Another explanation involves the generation and subsequent
selection of new subclones within the metastases or their
independent origin from the primary tumor.23 This heteroge-
neity may increase the ability of the tumor to face different
environmental challenges, and may explain the poor prognosis
of metastatic PTC. It is likely that, the methylation possibly
transforming to metastatsis is a feature of selective advantage
in tumor progression.
Inactivation of p16INK4a by methylation is a common and
early event in the development of cancer.24e26 Aberrant
methylation of p16 may be analogous to homozygous deletion,
leading to lack of p16 expression and a selective growth
advantage to tumor cells.3,27 Progressive methylation of the
p16 gene has been reported in early lesions of squamous
carcinomas of the lung28 and in 31% of cervical cancers.29
The highest frequency of p16 inactivation (30e40%) has
been reported in tumors of the colon, lung, brain, esophagus,
stomach, pancreas, and in 48% of lymphomas.30 The inci-
dence of p16 promoter hypermethylation in PTC have also
been reported, with frequencies reported to be three (25%) of
12, four (33%) of 12, seven (42%) of 16 and 18 (41%) of 44 in
four studies.15e18 Here, we detected methylation of p16 in
27% of thyroid carcinomas, which is consistent with 25%
frequency noted for silencing in a similar study.15
In conclusion, these results show that p16 promoter
hypermethylation in PTC appears to be associated with tumor
risk profile, invasive tumor behavior and development of
metastases. However, the patterns of CpG island hyper-
methylation in primary and metastatic PTC are complex.
Hypermethylation events present in both the primary and
metastatic tumors may be from events that were present very
early in the development of the primary tumor. Further tumor
evolution may proceed differently in various regions, either by
random chance or by selection because of different microen-
vironments. This may result in the formation of many unique
subpopulations with regard to methylation within the primary
tumor. In other words, the lack of hypermethylation seen in the
metastatic PTC at loci may be previously methylated in the
primary tumor. Therefore, it is strongly suggested that the
relationship between those patterns in any one patient may
require a more sophisticated explanation than a simple accu-
mulation of changes.
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